Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.
Nanjing Leads Biolabs Co., Ltd. announced that five of its research abstracts have been accepted for presentation at the 67th Annual Meeting of the American Society of Hematology. Among these, the clinical study of their drug candidate LBL-034 will be highlighted as the first oral presentation on the opening day, showcasing its promising efficacy and safety in treating relapsed/refractory multiple myeloma. This recognition at a prestigious event underscores the company’s advancements in hematology and strengthens its position in the biopharmaceutical industry.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in China, focusing on innovative drug development, particularly in the field of hematology. The company is involved in creating bispecific antibodies aimed at treating conditions like relapsed/refractory multiple myeloma.
Average Trading Volume: 896,173
Current Market Cap: HK$10.68B
See more data about 9887 stock on TipRanks’ Stock Analysis page.